



Peter Edman nominated as new board member

Lund, Sweden, 26 April 2019 – The Board of Xintela AB (publ) announces that Peter Edman has been nominated for election to the Board at the annual general meeting on the 27th of May 2019. Greg Batcheller, Karin Wingstrand and Sven Kili have been proposed for re-election. The proposal is supported by major shareholders of the company. It is also announced that board member Claes Post has decided not to stand for re-election.

Peter Edman (born 1954) has over 30 years of experience in drug development in leading positions from Orexo, Sobi, Biovitrum, AstraZeneca, Astra and Pharmacia. Peter has also worked at the Medical Products Agency and been a Professor at the Faculty of Pharmacy, Uppsala University. Peter Edman is currently working as an advisor and board member to companies in the Life Science sector. For the past two years, Peter has been a strategic advisor to Xintela and his election to the board will represent a deepening of his engagement with the company.

“Electing Peter Edman as a member of the Board will broaden Xintela’s expertise in development and commercialization in this stage of strong growth. His knowledge, experience and network of contacts are of great value to the company’s further development towards clinical studies and commercialization”, says Xintela’s Chairman of the Board Gregory Batcheller.

The Board would also like to thank Claes Post for his strong engagement and valuable contribution as a member of the Board since 2013 and wishes him every success with his ongoing and future assignments.

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO

Tel: 070-329 18 71

Email: evy@xintela.se

Medicon Village

223 81 Lund

www.xintela.se

About Xintela

Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem cells are safe and that they have a therapeutic effect on the articular cartilage and the underlying bone after an injury. Xintela has recently established its own GMP-facility to produce stem cells for clinical studies. In the oncology program, XINMARK® is used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against specific tumors with first focus on the aggressive brain tumor glioblastoma. Positive preclinical results from cell studies and animal model have shown that the ADC treatment has a targeting and killing effect on specific tumor cells supporting further development of the company’s oncology business. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.